SCHEMBL5222613

SCHEMBL5222613

COc1ccc(NC(=O)c2cccc(OC)c2N)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.63
KMT2A Q03164 5/20 0.63
NPC1 O15118 6/20 0.61
RAB9A P51151 5/20 0.61
METAP2 P50579 1/20 0.58
TP53 P04637 3/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
AHR P35869 1/20 0.58
MAPT P10636 1/20 0.58
MAPK1 P28482 1/20 0.58
KLKB1 P03952 1/20 0.58
GAA P10253 3/20 0.57
ALDH1A1 P00352 1/20 0.57
PNLIP P16233 1/20 0.57
POLB P06746 1/20 0.57
LMNA P02545 1/20 0.57
HTT P42858 1/20 0.56
KDM4E B2RXH2 1/20 0.55
KCNK3 O14649 1/20 0.55
KCNK9 Q9NPC2 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5403431 0.89 PNLIP (0.68) MEN1KMT2ANPC1RAB9AMETAP2
SCHEMBL28289265 0.88 KCNK3 (0.66) MEN1KMT2ANPC1RAB9ATP53
SCHEMBL7251420 0.88 RAB9A (0.77) MEN1KMT2ANPC1RAB9ATP53
SCHEMBL6593998 0.87 JAK2 (0.58) MEN1KMT2ANPC1RAB9ATP53
SCHEMBL14345353 0.87 KLKB1 (0.56) MEN1KMT2ANPC1RAB9ATP53
SCHEMBL5225897 0.86 NPC1 (0.74) MEN1KMT2ANPC1RAB9AMETAP2
SCHEMBL8408817 0.85 SMN1; SMN2 (0.58) MEN1KMT2ANPC1RAB9ATP53
SCHEMBL3949532 0.85 KMT2A (0.78) MEN1KMT2ANPC1RAB9AMETAP2
SCHEMBL5221779 0.82 RAB9A (0.65) MEN1KMT2ANPC1RAB9AMETAP2
SCHEMBL15361794 0.81 KLKB1 (0.53) MEN1KMT2ANPC1RAB9ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1014962-A4 ANTITHROMBOTIC AGENTS LILLY CO ELI (US) 2007-06-27 EP disclosed
US-6605626-B2 Benzamide inhibitors of factor Xa ELI LILLY AND COMPANY 2003-08-12 US disclosed
US-20020120007-A1 Benzamide inhibitors of factor Xa BEIGHT DOUGLAS WADE (US) 2002-08-29 US disclosed
US-6313122-B1 AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS ELI LILLY AND COMPANY 2001-11-06 US disclosed
EP-1014962-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 2000-07-05 EP disclosed
US-5948775-A OSTEOPOROSIS; ANTICANCER AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1999-09-07 US disclosed
WO-1999000121-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 1999-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120007-A1 Benzamide inhibitors of factor Xa TFPI, F11, F12 MEN1 1119/4885KMT2A 2083/4885NPC1 1618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.